Alexey Teplyakov
32Patents
8h-index
81Co-inventors
74Inventor score
Filing activity: Aug 11, 2009 → Jan 20, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9102737B2 | Human anti-CD27 antibodies, methods and uses | Chemistry; Metallurgy | 26 | Active |
| US9850310B2 | CD123 binding agents and uses thereof | Chemistry; Metallurgy | 12 | Active |
| US8722044B2 | Human tissue factor antibody and uses thereof | Chemistry; Metallurgy | 11 | Active |
| US9522957B2 | Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists | Chemistry; Metallurgy | 10 | Active |
| US9255153B2 | Polynucleotides encoding Toll-Like Receptor 3 antagonists | Chemistry; Metallurgy | 10 | Active |
| US8951525B2 | Human tissue factor antibody and uses thereof | Chemistry; Metallurgy | 9 | Active |
| US9481731B2 | Toll-like receptor 3 antagonists | Chemistry; Metallurgy | 9 | Active |
| US8999333B2 | Human tissue factor antibody and uses thereof | Chemistry; Metallurgy | 9 | Active |
| US9683046B2 | Nucleic acid molecules encoding anti-CD27 antibodies | Chemistry; Metallurgy | 7 | Active |
| US8323646B2 | Engineered anti-IL-13 antibodies, compositions, methods and uses | Physics | 6 | Active |
| US10562968B2 | Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US10844122B2 | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof | Chemistry; Metallurgy | 4 | Active |
| US9238693B2 | Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies | Chemistry; Metallurgy | 3 | Active |
| US8460659B2 | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases | Chemistry; Metallurgy | 2 | Active |
| US10301392B2 | Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies | Chemistry; Metallurgy | 2 | Active |
| US8409567B2 | Toll-like receptor 3 antagonists | Chemistry; Metallurgy | 2 | Active |
| US8399630B2 | Engineered anti-IL-13 antibodies, compositions, methods and uses | Physics | 2 | Active |
| US8540986B2 | Toll-like receptor 3 antagonists | Chemistry; Metallurgy | 2 | Active |
| US10544229B2 | Agonistic antibodies specifically binding CD40 and methods of use | Chemistry; Metallurgy | 1 | Active |
| US10829549B2 | Anti-CCL17 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US9944697B2 | Anti-CCL17 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US10562948B2 | GM-CSF variants and methods of use | Human Necessities | 1 | Active |
| US10669343B2 | Anti-CD154 antibodies and methods of using them | Chemistry; Metallurgy | 1 | Active |
| US11414484B2 | Anti-CCL17 antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US11787875B2 | Materials and methods for improved single chain variable fragments | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.